← Leaderboards
Jeffrey McCullough
University Of Minnesota Twin Cities
$5,022,716
Attributed
$5,022,716
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2005–14$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$3,476,716 · 3
CDC$1,546,000 · 1
By mechanism
U01$2,333,008 · 1
U2G$1,546,000 · 1
T32$931,300 · 1
P01$212,408 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Minnesota Twin Cities
Same institution · by research overlap
- Philip McGlave$1,430,518
- Dan S Kaufman$9,522,879
- Robert P Hebbel$14,706,560
- Daniel J Weisdorf$29,176,401
- Aneel Ashrani$2,079,731
Others in their field
Top investigators on “Thrombocytopenia”
- Thomas L Ortel · Duke University$23,613,789
- Mortimer Poncz · University Of Pennsylvania$19,917,641
- Joseph E Italiano · Brigham And Women'S Hospital$12,297,098
- Douglas Brock Cines · Duke University$11,304,101
- Gregory William Henkel · Arisan Therapeutics, Inc.$10,706,799
- Karin Maria Hoffmeister · Versiti Blood Health, Inc.$10,379,020
Research focus
ThrombocytopeniaClinical TrialsMedicineHemostatic FunctionMedicalAdoptionFacultyClinical Trials NetworkHemophilia AHemostatic AgentsInnovationInhibitor/AntagonistClinical ServicesEvolutionFundingBlood PlateletsConduct Clinical TrialsAreaBloodGranulocyteCaringDoseBlood BanksHeparin
Grant awards (25)
INCREASING THE AVAILABILITY OF SAFE BLOOD THROUGH BLOOD DONOR MOBILIZAITON IN THE$75,000
U2G · FY2014 · PS · contact PI
INCREASING THE AVAILABILITY OF SAFE BLOOD THROUGH BLOOD DONOR MOBILIZAITON IN THE$26,000
U2G · FY2014 · PS · contact PI
INCREASING THE AVAILABILITY OF SAFE BLOOD THROUGH BLOOD DONOR MOBILIZAITON IN THE$50,000
U2G · FY2013 · PS · contact PI
INCREASING THE AVAILABILITY OF SAFE BLOOD THROUGH BLOOD DONOR MOBILIZAITON IN THE$25,000
U2G · FY2013 · PS · contact PI
INCREASING THE AVAILABILITY OF SAFE BLOOD THROUGH BLOOD DONOR MOBILIZAITON IN THE$300,000
U2G · FY2012 · PS · contact PI
Clinical Trials in Transfusion Medicine and Hemostasis$163,516
U01 · FY2012 · HL · contact PI
INCREASING THE AVAILABILITY OF SAFE BLOOD THROUGH BLOOD DONOR MOBILIZAITON IN THE$10,000
U2G · FY2012 · PS · contact PI
INCREASING THE AVAILABILITY OF SAFE BLOOD THROUGH BLOOD DONOR MOBILIZAITON IN THE$10,000
U2G · FY2011 · PS · contact PI
INCREASING THE AVAILABILITY OF SAFE BLOOD THROUGH BLOOD DONOR MOBILIZAITON IN THE$1,050,000
U2G · FY2010 · PS · contact PI
Clinical Trials in Transfusion Medicine and Hemostasis$70,830
U01 · FY2010 · HL · contact PI
Clinical Trials in Transfusion Medicine and Hemostasis$186,875
U01 · FY2009 · HL · contact PI
Clinical Trials in Transfusion Medicine and Hemostasis$231,969
U01 · FY2008 · HL · contact PI
Clinical Trials in Transfusion Medicine and Hemostasis$186,875
U01 · FY2007 · HL · contact PI
Clinical Trials in Transfusion Medicine and Hemostasis$292,948
U01 · FY2006 · HL · contact PI
Clinical Trials in Transfusion Medicine and Hemostasis$300,000
U01 · FY2005 · HL
Clinical Trials in Transfusion Medicine and Hemostasis$300,000
U01 · FY2004 · HL
Clinical Trials in Transfusion Medicine and Hemostasis$300,000
U01 · FY2003 · HL
RESEARCH TRAINING IN TRANSFUSION MEDICINE$265,551
T32 · FY2003 · HL
RESEARCH TRAINING IN TRANSFUSION MEDICINE$353,589
T32 · FY2002 · HL
Clinical Trials in Transfusion Medicine and Hemostasis$299,995
U01 · FY2002 · HL
RESEARCH TRAINING IN TRANSFUSION MEDICINE$214,662
T32 · FY2001 · HL
Core--Cell processing$106,204
P01 · FY2001 · HD
Core--Cell processing$0
P01 · FY2001 · HD
Core--Cell processing$106,204
P01 · FY2000 · HD
RESEARCH TRAINING IN TRANSFUSION MEDICINE$97,498
T32 · FY2000 · HL